Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Amy Kidney

Nurse Practitioner, Obstetrics & Gynecology Bethpage, NY Nurse Practitioner

NPI 1710201371 CMS profile 10566480

4230 Hempstead Tpke Ste 208, Bethpage, NY 11714

Open in the dashboard

General payments

$3,396

136 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amy Kidney of Bethpage, NY is reported in the CMS Open Payments database as having received $3,396 across 136 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Nurse Practitioner, Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $489 24
2024 General $587 24
2023 General $998 33
2022 General $711 32
2021 General $612 23

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amy Kidney
  • Nurse Practitioner, Obstetrics & Gynecology median
  • Middle half of Nurse Practitioner, Obstetrics & Gynecology
  • National median

In program year 2025, general payments to Amy Kidney were reported at $489. Among 1,030 Nurse Practitioner, Obstetrics & Gynecology profiles paid that year, the median was $151 and the middle half received between $51 and $371.

Show as a table
Year Amy Kidney Nurse Practitioner, Obstetrics & Gynecology median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $612 $135 $40–$338 $132
2022 $711 $143 $45–$386 $149
2023 $998 $153 $54–$411 $160
2024 $587 $140 $45–$326 $164
2025 $489 $151 $51–$371 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $694 39 payments
  2. Vermillion, Inc. $488 7 payments
  3. Mayne Pharma Inc. $289 13 payments
  4. Myriad Women's Health, Inc. $280 1 payment
  5. Astellas Pharma US Inc $252 12 payments
  6. Hologic, LLC $219 5 payments
  7. Exeltis, USA Inc. $178 9 payments
  8. Myovant Sciences Inc. $150 7 payments
  9. CooperSurgical, Inc. $150 7 payments
  10. Evofem Biosciences, Inc. $143 8 payments
  11. Other $553 28 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,383 135 payments
  2. Education $13 1 payment
Products named General payments · program years 2021–2025
  1. OVA1 $488 7 payments
  2. LO LOESTRIN FE $348 17 payments
  3. LILETTA $327 21 payments
  4. myRisk $280 1 payment
  5. MYFEMBREE $268 12 payments
  6. Veozah $233 11 payments
  7. NOVASURE $144 2 payments
  8. ACESSA PROVU SYSTEM $121 1 payment
  9. Phexxi $109 6 payments
  10. PARAGARD T 380A $87 4 payments
  11. Other $938 47 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

136 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Obstetrics & Gynecology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record